Details of the Drug
General Information of Drug (ID: DM38Q7W)
Drug Name |
1,2-bis(4-fluorophenyl)ethane-1,2-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4,4'-Difluorobenzil; 579-39-5; 1,2-bis(4-fluorophenyl)ethane-1,2-dione; Ethanedione, bis(4-fluorophenyl)-; 4,4'-Difluorodibenzoyl; CHEMBL192410; 1,2-Ethanedione, 1,2-bis(4-fluorophenyl)-; BRKULQOUSCHDGS-UHFFFAOYSA-N; MFCD00134541; 1,2-Bis(4-fluorophenyl)-1,2-ethanedione; difluorobenzil; C14H8F2O2; 4,4'difluorobenzil; PubChem7683; ACMC-1AYLX; 4,4'-Difluorobibenzoyl; AC1L3VST; Benzil-based compound, 8; AC1Q5E6G; SCHEMBL716295; 4,4'-Difluorobenzil, 98%; DTXSID3060374; BDBM22730; MolPort-000-154-273; ZX-AP007762; ZINC2504724
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 246.21 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||